ISBT is the global knowledge network for Transfusion Medicine

About ISBT

The International Society of Blood Transfusion (ISBT) is a scientific society that was founded in 1935. Since that time the ISBT has grown in to an international society where transfusion medicine professionals from across the globe come together and do the one thing they do best: share knowledge to improve the safety of blood transfusion worldwide.

We believe that with the power of knowledge we can improve the safety of blood transfusion worldwide. Professionals from over 100 countries already share their knowledge with this international transfusion medicine community by being a member of ISBT.

Our mission

We are an international community of professionals sharing knowledge to enhance transfusion practice.

We achieve this by:

  • Providing opportunities for advancing knowledge and education
  • Advocacy for the welfare of blood donors and transfusion recipients

Activities

Our most important activity is to promote science and education related to blood, cells and transplantation. We have created an educational platform; ISBT Education. This eLearning facility includes webcasts of ISBT congress presentations, recordings of Webinars and Live Journal Clubs, and a library of transfusion guidelines. In addition we:

ANBI status

The ISBT has ANBI status. ANBI is the Dutch abbreviation for Public Benefit Organisation by The Dutch Tax and Customs Administration.

ISBT Central Office

The ISBT Central Office is located in the centre of Amsterdam, the Netherlands. With five fulltime colleagues and one part time colleague we:

  • Provide administrative and organisational support for the Board of Directors and Executive Committee.
  • Manage membership matters.
  • Coordinate International and Regional Congresses.
  • Facilitate content creation for ISBT Education.
  • Support the Standing Committees and Working Parties.
  • Edit and arrange for the distribution of ISBT's quarterly magazine Transfusion Today.
  • Operate as System Administrator for the ISBT website.

Meet the ISBT Team

Marnixstraat 317
1016 TB Amsterdam
The Netherlands
T: + 31 (0)20 7601 760
Email

Board of Directors

The ISBT Board of Directors is entrusted with the corporate governance and overall management of ISBT. The Board of Directors consists of the Executive Committee and nine Regional Directors. The Board delegates specific management and administrative functions to the Executive Committee which also works to ensure that the ISBT acts in accordance with Board decisions and with resolutions approved by members at the annual General Assembly. Read more

Standing Committees

The Standing Committees comprise a Chairperson and individual members chosen for their experience in the particular field of work. The ISBT has a number of Standing Committees:

DOWNLOADS

Medical Products of Human Origin

In May 2014 during the World Health Assembly in Geneva, Luc Noel (WHO Special Advisor- Service Delivery and Safety for the Initiative on Medical Products of Human Origin) set up a meeting involving representatives of four nongovernmental organisations in official relations with WHO to discuss a proposal relating to Medical Products of Human Origin (MPHO). The four organisations involved were The Transplantation Society (TTS), the Worldwide Network for Blood and Marrow Transplantation (WBMT), the International Society for Blood Transfusion (ISBT) and the International Council for Commonality in Blood Banking Automation (ICCBA).

Click here to download the ethical principles guiding the donation and procurement of Medical Products of Human Origin.

CORPORATE PARTNERS

We are honoured that seven companies are supporting ISBT as Gold Corporate partners:

We thank our Silver Corporate Partner:

We are thankful for the support of our Bronze Corporate partners:

Their valued support enables ISBT to continue facilitating knowledge about transfusion medicine and promoting a safe blood supply.

All levels of Corporate partners enjoy priority allocation at ISBT congresses for exhibition space and satellite symposia. Platinum and Gold partners have the opportunity to meet with members of the ISBT Executive committee and to work with ISBT when appropriate on educational activities.

We offer four levels of partnership:

  • Platinum
  • Gold
  • Silver
  • Bronze

For further information please contact Bodine van Wingerden

Gold Partners

Abbott is a health care company that is devoted to discovering new medicines, new technologies and new ways to manage health. The products span the continuum of care, from nutritional products laboratory diagnostics through medical devices and pharmaceutical therapies. For more information about Abbott, please visit their website: www.abbott.com

Since Bio-Rad was founded over six decades ago, they have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. For more information about Bio-Rad, please visit: www.bio-rad.com

Grifols is a global healthcare company whose mission is to improve the health and well being of people around the world. They accomplish this mission by producing life-saving protein therapies for patients and by providing hospitals, pharmacies and healthcare professionals with the tools they need to deliver expert medical care. For more information about Grifols, please visit: www.grifols.com.

Immucor plays a role in making blood transfusions safe for patients around the world. They market a complete line of traditional immunohematology reagents and fully automated instruments as well as data management software. For more information about Immcuor, please visit: www.immucor.com

With over 30 years of experience developing, manufacturing and commercializing blood-grouping reagents for the global transfusion diagnostics market, Quotient is focused on providing high quality, high value immunohematology products to hospitals and blood banks around the world. Quotient is nearing the commercialization of MosaiQ™, a next generation automation platform for transfusion diagnostics. For more information about Quotient, please visit: www.quotientbd.com 

Roche provides diagnostic tests and automation platforms used worldwide to improve the safety of blood products, increase laboratory efficiency, diagnose disease, monitor response to therapy and identify gene-based factors that may aid in treatment selection. For more information about Roche, please visit: www.roche.com

Terumo BCT serves blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices in more than 130 countries. It is their mission to improve lives through innovation, quality and services enabled by their technologies. For more information about Terumo BCT, please visit: www.terumobct.com

Silver Partners

DiaSorin develops, produces and distributes immunoreagent kits for clinical diagnostics. By making tests available that can provide guidance in making clinical decisions, DiaSorin has contributed to improving the delivery of health care and reducing its costs. For more information about DiaSoring, please visit: www.diasorin.com/en.

Bronze Partners

bioMérieux has been a global leader in in vitro diagnostics for more than 50 years, They have always been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide. Today, in more than 150 countries through 43 subsidiaries and a large network of distributors, bioMérieux provides diagnostic solutions that improve patient health and ensure consumer safety. Please visit: http://www.biomerieux.com/ for more information.

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. For more information please visit: http://cerus.com/ 

DIAGAST has designed, produced and marketed Immuno-Haematology (IH) solutions in over 60 countries for 30 years. The company offers a wide range of blood typing antibodies and ready-to-use reagents. With more than 40 clones and a high production capacity, DIAGAST is a major player in Transfusion. For more information about DIAGAST, please visit: www.diagast.com

Macopharma works to design innovative solutions and quality products that are effective in meeting the needs of both patients and healthcare providers. Every day across the world, Macopharma employees are dedicated to making therapeutic practices easier, better and safer. That is what they mean by the slogan “Designed for life.” For more information about Macopharma please visit: https://www.macopharma.com/

LINKS WITH OTHER TRANSFUSION MEDICINE SOCIETIES

AABB

ISBT and AABB recognise that their missions, aims, memberships and activities have common elements and while these may partially overlap they acknowledge that this provides a potential for synergy. The organisations believe in working together to utilise their respective strenghts and resources to pursue mutual and common interests. These are outlined in a memorandum of understanding signed in June 2017.
Click for more information.

AfSBT

ISBT and AfSBT have the capacity and knowledge to facilitate and share resources that will promote the development and strengthening of the practice of blood transfusion and the development of human resource capacity in Africa. Each of the Societies agrees in principle to utilise their respective strengths and resources to pursue mutual interests. These are outlined in a memorandum of understanding signed in 2014.
Click for more information.